## 1-[[2-(1,3-benzothiazol-2-ylthio)-1-oxoethyl]amino]-3-phenylthiourea: A Look at Its Importance
The compound you've mentioned, 1-[[2-(1,3-benzothiazol-2-ylthio)-1-oxoethyl]amino]-3-phenylthiourea, is a complex organic molecule with a rather long and descriptive chemical name. It's often referred to by its shorter name, **BTZT**, for simplicity.
**BTZT's Structure and Properties:**
BTZT is a derivative of thiourea, a molecule known for its ability to form strong hydrogen bonds. Its structure incorporates several important features:
* **Benzothiazole ring:** This aromatic ring is known for its fluorescence properties, making BTZT potentially useful in fluorescent probes or sensors.
* **Thiourea group:** This functional group is responsible for strong hydrogen bonding interactions with other molecules, potentially making BTZT a good candidate for binding to biomolecules like proteins or DNA.
* **Acetamide group:** This group adds further complexity to the molecule and potentially influences its biological activity.
**Why is BTZT Important for Research?**
BTZT and similar compounds have shown promise in various research areas, primarily due to their potential applications as:
* **Antimicrobial agents:** Studies have shown that BTZT exhibits antimicrobial activity against a range of bacteria and fungi. This could lead to the development of new antibiotic drugs.
* **Anti-cancer agents:** Some researchers have investigated the potential of BTZT and its analogs as anti-cancer agents, with promising results in inhibiting the growth of certain cancer cell lines.
* **Metal chelators:** BTZT's structure suggests it might act as a chelating agent, capable of binding to metal ions. This could have applications in areas like environmental remediation or metal-based drug delivery.
* **Fluorescent probes:** The benzothiazole ring in BTZT might be utilized to develop fluorescent probes for various biological applications, such as visualizing specific biomolecules or monitoring cellular processes.
**Key Considerations for Research:**
While BTZT shows promise, it is crucial to understand that its research is ongoing and needs further investigation.
* **Toxicity:** As with any new compound, thorough safety testing is essential to assess BTZT's potential toxicity and side effects before considering any therapeutic use.
* **Pharmacokinetic properties:** Further research is needed to understand how BTZT is absorbed, distributed, metabolized, and excreted within the body to optimize its delivery and effectiveness.
* **Mechanism of action:** Identifying the specific mechanisms by which BTZT exerts its antimicrobial, anti-cancer, or other effects is crucial to understand its potential applications and develop more targeted therapies.
**Conclusion:**
1-[[2-(1,3-benzothiazol-2-ylthio)-1-oxoethyl]amino]-3-phenylthiourea (BTZT) is a complex organic molecule with a promising future in research. Its potential applications in various fields, including antimicrobial, anti-cancer, and fluorescent probe development, warrant further investigation and highlight the importance of continued research into this fascinating compound.
ID Source | ID |
---|---|
PubMed CID | 1553611 |
CHEMBL ID | 1345374 |
CHEBI ID | 122001 |
Synonym |
---|
MLS000591387 |
smr000219015 |
CHEBI:122001 |
2-[(1,3-benzothiazol-2-ylsulfanyl)acetyl]-n-phenylhydrazinecarbothioamide |
STL071029 |
1-[[2-(1,3-benzothiazol-2-ylsulfanyl)acetyl]amino]-3-phenylthiourea |
HMS2513G09 |
AKOS005641587 |
HMS3375G08 |
CHEMBL1345374 |
Q27210627 |
1-[[2-(1,3-benzothiazol-2-ylthio)-1-oxoethyl]amino]-3-phenylthiourea |
2-[(1,3-benzothiazol-2-ylthio)acetyl]-n-phenylhydrazinecarbothioamide |
Class | Description |
---|---|
benzothiazoles | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 15.8114 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 11.2202 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
phosphopantetheinyl transferase | Bacillus subtilis | Potency | 79.4328 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 0.7079 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 8.9125 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
PINK1 | Homo sapiens (human) | Potency | 31.6228 | 2.8184 | 18.8959 | 44.6684 | AID624263 |
regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 50.1187 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 0.8913 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
Parkin | Homo sapiens (human) | Potency | 31.6228 | 0.8199 | 14.8306 | 44.6684 | AID624263 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 3.5481 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 12.5893 | 0.0018 | 15.6638 | 39.8107 | AID894 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 2.7334 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
geminin | Homo sapiens (human) | Potency | 19.7347 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |